Back to Search
Start Over
How should we manage bevacizumab toxicity in lung cancer patients?
- Source :
- Lung Cancer Management. 3:355-363
- Publication Year :
- 2014
- Publisher :
- Future Medicine Ltd, 2014.
-
Abstract
- SUMMARY Bevacizumab is an antiangiogenic targeted therapy approved for the treatment of patients with advanced non-small-cell lung cancer other than predominantly squamous cell histology in addition to platinum-based chemotherapy. The safety of bevacizumab has been assessed in studies across most cancer types and bevacizumab is generally well tolerated. Some specific issues associated with the use of bevacizumab in lung cancer are discussed in this report (pulmonary hemorrhage, brain metastases or concurrent thoracic radiotherapy) as well as frequent and clinically relevant adverse events and their management. Oncologists and pulmonologists should be aware of such events and their management since the prescription of bevacizumab concerns many patients and the future use in maintenance therapy will be associated with prolonged treatment.
- Subjects :
- Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Chemotherapy
genetic structures
Bevacizumab
business.industry
medicine.medical_treatment
Cancer
medicine.disease
eye diseases
Targeted therapy
Maintenance therapy
Internal medicine
medicine
Pulmonary hemorrhage
Lung cancer
Adverse effect
business
medicine.drug
Subjects
Details
- ISSN :
- 17581974 and 17581966
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- Lung Cancer Management
- Accession number :
- edsair.doi...........424328d458769eba0c6daa32f0723901
- Full Text :
- https://doi.org/10.2217/lmt.14.25